Follow-up of Chronic HBV Infected Patients Planned Chemotherapy Due to Solid Organ Malignancy


Creative Commons License

ERDEM H. A. , PULLUKÇU H. , TAŞBAKAN M. , SİPAHİ O. R. , ULUSOY S. , SERTOZ R., ...Daha Fazla

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.27, ss.213-219, 2017 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 27 Konu: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4999/uhod.171914
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Sayfa Sayıları: ss.213-219

Özet

The aim of this study was to screen the patients with solid organ malignancy for HBV (Hepatitis B virus) infection before the start of chemotherapy and follow up in the oncology department of our setting. All cases admitted to oncology department for chemotherapy were screened prospectively for HBV infection and reactivation between March 2013-September 2014. A total of 225 patients were included in the study and divided into 3 groups; Group I: having recovered past HBV infection: 43 patients (19.1%), Group II: isolated Anti-HBcAg total positive: 20 patients (8.9%) and Group III: chronic HBV infection with 10 patients (4.4%). HBV reactivation developed in one (5.9%) of 17 patients in group II, and two (28.6%) of seven patients in group III while under lamivudine prophylaxis. Neither hepatitis flare by HBV reactivation nor HBV-related death were observed in our study. In the moderate endemicity areas like Turkey for HBV infection, all patients must be screened for HBV before starting of chemotherapy.